GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocugen Inc (FRA:2H51) » Definitions » Cyclically Adjusted Price-to-FCF

Ocugen (FRA:2H51) Cyclically Adjusted Price-to-FCF : (As of Apr. 30, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Ocugen Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Ocugen Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Ocugen's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocugen Cyclically Adjusted Price-to-FCF Chart

Ocugen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Ocugen Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Ocugen's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Ocugen's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ocugen's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ocugen's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Ocugen's Cyclically Adjusted Price-to-FCF falls into.



Ocugen Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Ocugen's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Ocugen's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.05/129.4194*129.4194
=-0.050

Current CPI (Dec. 2023) = 129.4194.

Ocugen Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201403 -17.446 99.695 -22.648
201406 -19.070 100.560 -24.543
201409 -18.017 100.428 -23.218
201412 -24.451 99.070 -31.941
201503 -40.336 99.621 -52.401
201506 -31.877 100.684 -40.975
201509 -29.756 100.392 -38.360
201512 -29.606 99.792 -38.396
201603 -31.991 100.470 -41.209
201606 -27.484 101.688 -34.979
201609 -21.923 101.861 -27.854
201612 -18.949 101.863 -24.075
201703 -18.912 102.862 -23.795
201706 -13.632 103.349 -17.071
201709 -12.907 104.136 -16.041
201712 -9.430 104.011 -11.734
201803 3.573 105.290 4.392
201806 -11.958 106.317 -14.556
201809 -10.573 106.507 -12.848
201812 -5.960 105.998 -7.277
201903 -5.604 107.251 -6.762
201906 -1.715 108.070 -2.054
201909 0.482 108.329 0.576
201912 -0.150 108.420 -0.179
202003 -0.081 108.902 -0.096
202006 -0.033 108.767 -0.039
202009 -0.016 109.815 -0.019
202012 -0.020 109.897 -0.024
202103 -0.025 111.754 -0.029
202106 -0.094 114.631 -0.106
202109 -0.035 115.734 -0.039
202112 -0.058 117.630 -0.064
202203 -0.067 121.301 -0.071
202206 -0.066 125.017 -0.068
202209 -0.071 125.227 -0.073
202212 -0.081 125.222 -0.084
202303 -0.082 127.348 -0.083
202306 -0.084 128.729 -0.084
202309 -0.062 129.860 -0.062
202312 -0.050 129.419 -0.050

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Ocugen  (FRA:2H51) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Ocugen Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Ocugen's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Ocugen (FRA:2H51) Business Description

Industry
Traded in Other Exchanges
Address
11 Great Valley Parkway, Malvern, PA, USA, 19355
Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. The breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug one to many and novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy. The company is co-developing Bharat Biotech's COVAXIN vaccine candidate for COVID-19 in the U.S. and Canadian markets.

Ocugen (FRA:2H51) Headlines

No Headlines